EXAMINE THIS REPORT ON HEMGENIX

Amount of suitable clients: CDEC talked over the uncertainty in the volume of people with reasonably intense to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be categorised as acquiring delicate or reasonable illness might have a serious bleed